Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer

Cartwright, Thomas H.; Cohn, Allen Lee; Varkey, Jerry A.; Chen, Yin-Miao; Szatrowski, Ted P.; Cox, John V.; Schulz, Joseph J.

doi:10.1200/jco.2002.20.1.160

Cited by 80 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to these administration approaches, oral administration has its own advantages. It is safer, more convenient, and more tolerable for patients (48). OP-D is a saponin containing several glycosidic bonds.…”

Section: Discussionmentioning

confidence: 99%

Ophiopogonin D alleviates high‐fat diet‐induced metabolic syndrome and changes the structure of gut microbiota in mice

Chen

Liu

et al. 2018

FASEB j.

View full text Add to dashboard Cite

Gut dysbiosis is believed to play a critical role in the pathogenesis of metabolic diseases, including obesity. Ophiopogonin D (OP-D), a steroidal glycoside and an active component extracted from the root of the plant Ophiopogon japonicus (also known as radix ophiopogonis), can regulate multiple physiologic processes. Here we show that OP-D administration reduces body weight, hyperglycemia, hyperlipidemia, and insulin resistance in male mice fed a high-fat diet (HFD). Pyrosequencing of the V4 regions of 16S rRNA genes in mouse feces revealed a deviation of the gut microbiota in response to OP-D treatment. In particular, the decreased Firmicutes-to- Bacteroidetes ratios and endotoxin-bearing Proteobacteria levels indicated that OP-D reversed HFD-induced gut dysbiosis. More importantly, the effects of OP-D on modulation of obesity and microbiota were transferable via horizontal feces transfer from OP-D-treated mice to HFD-fed mice. Taken together, our results suggest that OP-D may be used as a prebiotic agent to treat obesity-associated gut dysbiosis and metabolic syndrome.-Chen, S., Li, X., Liu, L., Liu, C., Han, X. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Ophiopogonin D alleviates high‐fat diet‐induced metabolic syndrome and changes the structure of gut microbiota in mice

Chen

Liu

et al. 2018

FASEB j.

View full text Add to dashboard Cite

show abstract

“…It has proved to be active for therapy in PDAC 21. Thus, a combination of capecitabine and oxaliplatin (XELOX) is also expected to be as effective as the combination of 5-FU and oxaliplatin, used as a second-line regimen for PDAC patients whose cancers have progressed after treatment with a gemcitabine-based regimen.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy

et al. 2017

View full text Add to dashboard Cite

Background/AimsSecond-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients.MethodsBetween August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m2 twice daily for 14 days; oxaliplatin, 130 mg/m2 on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed.ResultsSixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatment-related mortality caused by severe neutropenia and typhlitis.ConclusionsSecond-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabine-based chemotherapy.

show abstract

“…For decades, 5-FU has been the only drug displaying even a glimmer of activity [57][58][59]. More recently, the 5-FU prodrug, capecitabine, evoked a 25% clinical benefit response and a 7.3% objective response [60]. However, with the development of gemcitabine, clinical trials suggested an improvement in both quality of life and survival of patients receiving this drug despite a relatively low objective response rate of only 5% [61•,62].…”

Section: Systemic Chemotherapymentioning

confidence: 99%

Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma

Marsh

George²

2006

Curr Gastroenterol Rep

View full text Add to dashboard Cite

The emergence of effective systemic chemotherapy, along with the parallel development of new targeted cell signal inhibitors for pancreatic cancer treatment, has provided impetus for a re-examination of the appropriate use of chemotherapy and radiation therapy in this malignancy. In addition to exciting developments in the treatment of locally advanced and metastatic disease, new data have emerged regarding the efficacy of adjuvant and neoadjuvant therapy when combined with traditional surgical approaches such as a Whipple procedure. This review summarizes the sentinel clinical trials and discoveries that have influenced the development and deployment of scientifically based multidisciplinary care for today's patients, with a particular focus on modern radiation and chemotherapy.

show abstract

Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer

Cited by 80 publications

References 14 publications

Ophiopogonin D alleviates high‐fat diet‐induced metabolic syndrome and changes the structure of gut microbiota in mice

Ophiopogonin D alleviates high‐fat diet‐induced metabolic syndrome and changes the structure of gut microbiota in mice

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy

Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About